Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer by Borrego Soto, Gissela et al.
Ionizing radiation-induced DNA injury and damage detection
in patients with breast cancer
Gissela Borrego-Soto1,2, Rocío Ortiz-López1,2 and Augusto Rojas-Martínez1,2
1Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina,
Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
2Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autónoma de Nuevo León,
Monterrey, Nuevo León, Mexico.
Abstract
Breast cancer is the most common malignancy in women. Radiotherapy is frequently used in patients with breast
cancer, but some patients may be more susceptible to ionizing radiation, and increased exposure to radiation
sources may be associated to radiation adverse events. This susceptibility may be related to deficiencies in DNA re-
pair mechanisms that are activated after cell-radiation, which causes DNA damage, particularly DNA double strand
breaks. Some of these genetic susceptibilities in DNA-repair mechanisms are implicated in the etiology of hereditary
breast/ovarian cancer (pathologic mutations in the BRCA 1 and 2 genes), but other less penetrant variants in genes
involved in sporadic breast cancer have been described. These same genetic susceptibilities may be involved in
negative radiotherapeutic outcomes. For these reasons, it is necessary to implement methods for detecting patients
who are susceptible to radiotherapy-related adverse events. This review discusses mechanisms of DNA damage
and repair, genes related to these functions, and the diagnosis methods designed and under research for detection
of breast cancer patients with increased radiosensitivity.
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Background
Breast cancer is the leading cause of cancer morbidity
and death in women in developed countries and countries
with emerging economies (Ripperger et al., 2009; Youlden
et al., 2012). According to Globocan, 1.67 million new
cases of breast cancer were diagnosed in 2012 and ranks as
the fifth cause of death from cancer overall (522,000
deaths). A global increase has been estimated to around
16,500 yearly new cases of this neoplasia by 2020. (Knaul
et al., 2009)
Radiation therapy is an efficient treatment for cancer.
About 50% of patients with malignant breast tumors re-
ceive radiation therapy and most patients seem tolerate it,
but some suffer severe adverse effects induced by the ther-
apy. This variability of response may be caused by several
factors, like age, life style, inflammatory responses, oxida-
tive stress, genetic predisposition and variants in genes in-
volved in the response to radiation-induced DNA damage
(Smirnov et al., 2012; Hornhardt et al., 2014). Therefore, it
is important to develop new diagnostic techniques for pre-
dicting responses to cancer treatment and for identifying
patients susceptible to radiation-related toxicity.
Any disturbance that results in the loss of genomic in-
tegrity may induce cell cycle deregulation and uncontrolled
cell proliferation. Cells are continuously exposed to DNA
damaging agents and have developed mechanisms to re-
spond to genome damage. Double-strand DNA breaks
(DSB), although rare, are perhaps the most lethal mecha-
nism and are often produced by ionizing radiation (Pastink
et al., 2001; Siever et al., 2003). The BRCA-1 and BRCA-2
proteins are involved in DSB damage repair, and several
mutations in these genes increase the risk for developing
breast and other neoplasias (Roy et al., 2012).
Ionizing Radiation-Associated DNA Damage,
Radiotherapy and Mechanisms of DNA Repair
Ionizing radiation effects in the cell
Ionizing radiation is a type of high-energy radiation
that is able to release electrons from atoms and molecules
generating ions which can break covalent bonds. Ionizing
radiation directly affects DNA structure by inducing DNA
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breaks, particularly, DSBs. Secondary effects are the gen-
eration of reactive oxygen species (ROS) that oxidize pro-
teins and lipids, and also induce several damages to DNA,
like generation of abasic sites and single strand breaks
(SSB). Collectively, all these changes induce cell death and
mitotic failure.
Ionizing radiation can be divided into X-rays, gamma
rays, alpha and beta particles and neutrons. Quiescent and
slowly dividing cells are less radiosensitive, like those con-
stituting the nervous system, while cells with high prolifer-
ation rates are more radiosensitive, like bone marrow, skin,
and epithelial cells of the gastro-intestinal tract, among oth-
ers. The radiation dose is measured in units gray (Gy), a
measure of the amount of radiation absorbed by 1 kg of tis-
sue (Dunne-Daly, 1999).
Radiotherapy
Radiotherapy is a treatment aimed at shrinking the tu-
mor mass or at eliminating residual tumor cells by exposing
the tumor to ionizing radiation. Radiotherapy regimes
mostly use X- and gamma radiation (Masuda and Kamiya,
2012). Radiation affects tumor and healthy irradiated cells
indistinctly. Radiotherapy is used as the standard treatment
for breast cancer after mastectomy; but this therapy may be
also used prophylactically or palliatively to reduce the risk
of tumor recurrence or to relieve symptoms caused by tu-
mor growth and associated metastases, respectively (Dela-
ney et al., 2005). Radiation therapy can be delivered by
external-beam radiation or internal radiation. External-
beam radiation therapy is created electronically by a linear
accelerator which produces photon beams known as
X-rays, with electric potentials in the range of 4 to 20 mega
Volts. Patients receive radiation doses in daily sessions for
several weeks, and the radiation dose may be administered
in three different schemes: accelerated fractionation,
hyperfractionation and hypofractionation. Accelerated
fractionation means a radiation scheme in which the total
dose of radiation is divided into small doses, and the treat-
ments are given more than once per day. The total dose of
radiation is administered in a shorter period of time (fewer
days) compared to standard radiation therapy (weeks). A
reduction in the treatment time may reduce the repopula-
tion of tumor cells, resulting in a better locoregional con-
trol. In hyperfractioned treatment, the total radiation dose is
divided into smaller doses, and it is administered more than
once a day; but in the same period as standard radiotherapy
(days or weeks). Dose reduction may reduce the toxicity
risk, although the total dose is increased. Hypofractionated
radiation treatment is given once a day or less often. The to-
tal dose is divided into larger doses and is administered
over a shorter period than standard radiotherapy. This
scheme reduces patient visits and cost, and fewer side ef-
fects are noticed when compared to conventional radiation
therapy.
The internal radiation therapy, also called brachy-
therapy, is released from gamma-radiation sources such as
radioactive isotopes like 60Co and 137Cs, which are placed
within the patient’s body. This type of radiation can deliver
high doses of focalized radiation with an electric potential
in the range of 0.6 to 1 megaVolt and causes less damage to
normal tissues (Patel and Arthur, 2006).
DNA repair after ionizing radiation
Ionizing radiation causes DSBs directly, but in addi-
tion base damages due to indirect effects are also induced.
This radiation causes formation of ROS (reactive oxygen
species) which are indirectly involved in DNA damage.
These ROS generates apurinic / apyrimidinic (abasic) sites
in the DNA, SSBs, sugar moiety modifications, and deami-
nated adducted bases (Redon et al., 2010; Aparicio et al.,
2014). When DNA is damaged, the repair machinery of the
cell is activated and stops the cell cycle at specific control
checkpoints to repair DNA damage and prevent continua-
tion of the cycle. It is known that the intrinsic radiosen-
sitivity of tumor cells is strongly influenced by the cells
DSB repair capability (Mladenov et al., 2013). If tumor
cells are able to efficiently repair the radiation damage, re-
sistance to radiation develops, enabling cells to survive and
replicate. If the damage remains unrepaired, these mecha-
nisms induce programmed cell death or apoptosis to pre-
vent accumulation of mutations in daughter cells (Deckbar
et al., 2011; Guo et al., 2011).
As mentioned, ionizing radiation inevitably reaches
normal tissue, inducing bystander effects in tumor-adjacent
normal cells that may contribute to chromosomal aberra-
tions and to increase the risk for new malignancies. High
doses of radiation may produce toxicity and reduce the pa-
tient’s prognosis (Brown et al., 2015). Individual radiation
treatment based on DSB repair capability could predict tox-
icity to surrounding tissues, thereby improving treatment
safety. DSB repair capability depends not just on gene in-
tegrity, but also on gene expression. In addition to germinal
mutations affecting genes like BRCA 1 and 2 or other re-
lated genes, genetic and epigenetic mechanisms may re-
duce or abrogate the expression of genes involved in DSB
repair (Bosviel, et al., 2012). The DNA repair capability
could be relevant to decide on the appropriate treatment for
cancer patients, and functional tests may provide valuable
information for these clinical decisions.
DSB repair pathways
DSB repair is achieved in three ways: non-homo-
logous end joining (NHEJ), conservative homologous re-
combination (HR) and single-strand alignment, also called
non-conservative homologous recombination (SSA) (Lan-
gerak and Russell, 2011). HR is considered an error-free
mechanism because it uses an undamaged DNA guide
strand to repair the DSB, and the original DNA is reconsti-
tuted without loss of genetic information, but this mecha-
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nism proceeds slowly and is only exerted at the S/G2
phases of the cell cycle. NHEJ and SSA are considered er-
ror-prone and mutagenic mechanisms because the process-
ing of DNA ends may incur in loss or modification of
genetic information at the repaired DSB ends. NHEJ is the
most common mechanism of DSB repair in eukaryotic
cells. In this mechanism, the DNA strands at the DSB are
cut or modified, and the ends are ligated together regardless
of homology, generating deletions or insertions. Although
this process is error-prone, this mechanism can fix the DNA
damage quickly, because it is not restricted to a single cell
cycle phase, thus preventing increased genetic instability
(Do et al., 2014). These mechanisms are detailed below and
in the Figure 1. The main proteins involved in the early
steps of DSB detection, chromatin remodeling and DNA
repair are listed in Table 1.
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Figure 1 - DSB repair pathways. In NHEJ, the KU70/KU80 heterodimer binds to the DSB, protects it from degradation by exonucleases, and acts as a
repressor of HR. The KU70/80 heterodimer recruits and activates the DNA-PKcs and KU70 interacts with XRCC4. Then, the DNA ligase IV interacts
with the KU heterodimer to ligate the DNA ends. If required for ligation, PNKP binds to phosphorylated XRCC4 to process the DNA ends. In the HR
pathway the MRN complex is recruited at the DSB ends and CtIP binds to the MRN complex activating an exonuclease activity which creates single
strand segments at the borders of the DSB that are extended by the EXO1 3’- 5’ exonuclease. Then, hSSB1 binds to free ends and RPA (an heterometic
complex formed by RPA70, RPA32 and RPA14) protects against degradation. RPA is replaced by RAD51-BRCA2. RAD51 nucleoprotein searches for
and invades the homologues sequences, from sister chromatid, to form a Holliday junction. The sister chromatids are joined by cohesin proteins to facili-
tate the interconnection of the DSB to the homologous recombination. Subsequently, RAD51 is removed leaving a free 3’-OH and DNA is synthesized by
the DNA polymerase  using the homologous chromatid as a template. Resolvase enzymes solve the Holliday junction and the DNA ends are joined by
DNA ligase I. The SSA pathway is not conservative and depends on the presence of repeated sequences flanking the DSB. In this mechanism, the MRN
complex joined to CtIP cleaves the 5’-end of one strand of DNA to expose microhomology sequences. Homologous sequences are aligned, while
nonaligned regions are removed by the ERCC1/XPF nucleases. Then, DNA ends are joined by DNA ligase III.
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Table 1 - DNA repair and cell cycle control genes.
Gene Name Function Cromosomal
location
AKT1 v-akt murine thymoma viral oncogene
homolog 1
Serine/threonine kinase. Regulates components of the
apoptotic machinery.
14q32.32
ATM Ataxia telangiectasia mutated Serine threonine protein kinase. Activates cell cycle check-
points upon DSB induction acting as a DNA damage sensor.
11q22-q23
BAP1 BRCA1 associated protein-1 (ubiquitin
carboxy-terminal hydrolase)
Binds to BRCA1. Involved in cell cycle, response to DNA
damage and chromatin dynamics.
3p21.1
BIRP1 BRCA1 protein interaction with c-terminal
helicase
Receptor-interacting protein forming a complex with
BRCA1. Active during DSB repair.
17q22.2
BRCA1 Breast cancer 1 DNA repair, ubiquitination and transcriptional regulation to
maintain genomic stability. Induces cell cycle arrests after
ionizing irradiation.
17q21
BRCA2 Breast cancer 2 Involved in DSB repair and/or homologous recombination in
meiosis.
13q12
CDKs Cell Division Protein Kinase Cell cycle kinases. 10q21.2
CDKN1B Cyclin-dependent kinase inhibitor 1B Cell-cycle progression at G1. 12p13.1-p12
CCND1 Cyclin D1 Regulates cell cycle during G1/S, also interacts with a net-
work of repair proteins including RAD51 to regulate HR
11q13
CCND3 Cyclin D3 Regulates G1/S transition in cell cycle 6p21.1
RBBP8 Retinoblastoma Binding Protein Endonuclease that functions with MRX complex in the first
step of the DSB repair.
18q11.2
EP300 3 00 kDa E1A-Binding protein gene Regulates transcription via chromatin remodeling. Regulated
by acetylation in DNA damage response.
22q13.2
EXO1 Exonuclease 1 5’-3’ Exonuclease 1q43
FGFR2 Fibroblast growth factor receptor 2 Cell surface tyrosine kinase receptor regulating cell prolifer-
ation, migration and apoptosis.
10q25.3-q26
HIST1H2BC Histone cluster 1, H2BC Core histone playing roles in DNA repair, replication and
chromosomal stability.
6p22.1
H2AX H2A Histone Family, Member X Required for checkpoint-mediated arrest of cell cycle pro-
gression in response to low doses of ionizing radiation and
for efficient DSB repair when modified by C-terminal
phosphorylation.
11q23.3
KU70 Thyroid Autoantigen 70 kDa Binding to DSB ends and inhibition of exonuclease activity
at these ends.
22q13.2
LIG4 Ligase IV DNA ligase involved in DNA non-homologous end joining
(NHEJ) required for DSB repair.
13q33.3
LSP1 Lymphocyte-specific protein 1 Actin binding protein F. 11p15.5
MDC1 Mediator of DNA Damage Checkpoint 1 Mediator-adaptor protein in response to DNA damage, active
during the S and G2/M phases of cell cycle.
6p21.3
MLL3 Myeloid/lymphoid or mixed-lineage leukae-
mia 3
Part of the ASCOM complex regulated by acetylation to in-
duce expression of p53 targets such as p21 in DNA damage
response.
7q36.1
MRE11 Meiotic Recombination 11 Endonuclease, exonuclease, MRN/X complex-5. 11q21
NBN1 Nibrin Component of the MRN/X complex. Plays a critical role in
the cellular response to DNA damage and the maintenance of
chromosome integrity. Regulator of cell cycle checkpoints in
meiosis.
8q21.3
PALB2 Partner and localizer of BRCA Critical role in HR repair by recruiting BRCA2 and RAD51. 16p12.1
PTEN Phosphatase and tensin homolog Tumor suppressor protein. Active in DNA repair through in-
teractions with the Chk1 and the P53 pathways. Regulator of
the RAD51 activity.
10q23.3
RAD50 RAD50 homolog Sacharomyces cerevisiae Protein involved in DSB repair, required for NHEJ and HR. 5q23-q31
RAP80 Ubiquitin Interaction Motif Containing 1 Recognize ubiquitinated H2A and H2AX histones and re-
cruits the BRCA1/BARD1 heterodimer at DSB.
5q35.2
Non-homologous end joining (NHEJ)
Canonical NHEJ (C-NHEJ) is a conservative end-
joining process, and this pathway is also essential for V(D)J
recombination during T- and B-cell lymphocyte develop-
ment. NHEJ is not restricted to a particular phase of the cell
cycle, but occurs preferentially during the G0, G1 and the
early S phases (Chistiakov et al., 2008; Deckbar et al.,
2011; Malu et al., 2012a,b). NHEJ involves ligation of
break DNA ends and does not require sequence homology.
The first step in the process is the recognition of the DNA
ends by the KU heterodimer composed by the KU70 and
KU80 proteins. The heterodimer binds to DNA ends and
protects them from further degradation (Williams et al.,
2014). Crystallographic studies of the KU70/80 hetero-
dimer showed that it adopts a ring-shaped structure encir-
cling the duplex DNA helix which reaches the DNA ends
(Walker et al., 2001). The KU subunits are similar in do-
main organization; they have an amino-terminal von Wille-
brand domain participating in the KU heterodimerization
(Fell and Schild-Poulter, 2012). The KU70/80 heterodimer
forms a scaffold at the DNA ends and recruits and activates
the DNA-dependent protein kinase catalytic subunit
(DNA-PKcs). DNA-PKcs form a pincer-shaped structure
which creates a central channel mediating the ability of
DNA-PKcs to bind double strand DNA (Sibanda et al.,
2010; Davis et al., 2014). Subsequently, the X-ray repair
complementing defective repair protein in Chinese hamster
cells 4 (XRCC4) interacts with the KU70 subunit and an-
other critical NHEJ scaffolding protein, enabling enzymes
to interact with the DSB region. DNA ligase IV directly in-
teracts with the KU heterodimer, an interaction mediated
by the tandem BRCA1 C-terminal (BRCT) domains found
in the C- terminus of DNA ligase IV (Ochi et al., 2014).
Next, the PNKP (polynucleotide kinase-phosphatase) in-
teracts with phosphorylated XRCC4. Structural analysis
showed that this scaffold forms filaments interacting with
the DNA ends and forms a bridge which stabilizes the ends
of the DSB (Hammel et al., 2010; Ochi et al., 2014). It has
also been shown that XRCC4 joins to unphosphorylated
PNKP, but with less affinity. Other proteins, such as apra-
taxin, aprataxin and PNKP like factor (APLF), and
XRCC4-like factor (XLF) also bind XRCC4.
Usually, DSB ends are irregular and show other de-
fects, like abasic strand segments that must be solved be-
fore NHEJ occurs. If phosphate or adenylate groups are
present at the DSB ends, DNA end processing may be re-
quired for subsequent ligation. PNKP is a kinase/phos-
phatase responsible for adding phosphate to the 5 ‘OH end
and remove the phosphate groups at the 3’ end (Bernstein et
al., 2005). Aprataxin is a nucleotide hydrolase and trans-
ferase which catalyzes the removal of adenylate groups co-
valently linked to 5’ phosphate termini (Grundy et al.,
2013). When DSB asymmetries must be fixed, the exo-
nuclease Artemis is phosphorylated and binds to DNA-
PKcs to trim redundant ends. KU has 5’deoxyribose-5-
phosphate (5’-dRP)/AP lyase activity involved in cleaving
redundant abasic single strands present at DSB ends (Rob-
erts et al., 2010). The Werner syndrome Rec Q helicase like
protein (WRN) joins the KU heterodimer and XRCC4 and
stimulate an exonuclease 3’ to 5’ activity (Gu et al., 2010;
Malu et al., 2012). Sometimes filling of gaps in the strands
at the DSB site is required, and this function may be accom-
plished by the X family polymerases ( and  polymerases)
(Capp et al., 2006, 2007).
When DSB ends of two DNA segments are clean and
compatible they are ligated by DNA ligase IV (Jahan et al.,
2014). Ligase IV activity is stimulated by XRCC4 (Gu et
al., 2007). Incompatible ends may be joined by an interac-
tion between ligase IV and XLF.
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Gene Name Function Cromosomal
location
RB1 Retinoblastoma Tumor suppressor protein, mediates cell cycle arrest. 17q22.2
Rif1 RAP1 interacting factor homolog (yeast) Required for cell cycle arrest at S-phase in response to DNA
damage.
2q23.3
RNF168 RING Finger Protein E3 ubiquitin-protein ligase required for recruiting repair pro-
teins to DNA damage sites.
3q29
TGF1 Transforming growth factor 1 Multifunctional peptides that regulate cell proliferation, mi-
gration, adhesion, differentiation, and other functions.
19q13.1
TopBP1 Topoisomerase (DNA) II Binding Protein S-phase checkpoint regulator. 3q22.1
TOX3 Tox high mobility group box family member 3 Involved in alteration of chromatin structure. 16q12.1
TP53 Tumor protein p53 Tumor suppressor protein, cell cycle arrest, apoptosis, senes-
cence and DNA repair.
17p13
XLF/Cernunnos Non homologous End-Joining Factor Scaffold protein. Serve as a bridge between XRCC4 and the
other NHEJ factors.
2q35
XRCC4 X-Ray Repair Complementing Defective Scaffold protein involved in NHEJ. 5q14.2
53BP1 Tumor Protein P53 Binding Protein Adaptor protein, chromatin reader. Promotes NHEJ. 15q15.3
Table 1 - cont.
There is also an alternative NHEJ pathway (A-NHEJ)
which is independent of the KU70/KU80 heterodimer ac-
tivity. In this mechanism, DNA ends are excised by the
meiotic recombination 11 protein (MRE11) and the retino-
blastoma binding protein 8 (RBBP8, synonymous of CtIP)
exonucleases (Gu et al., 2010, Hammel et al., 2010), expos-
ing microhomology regions which can be aligned, allowing
the filling of the empty segments by the X family poly-
merases. Thereafter, XRCC1 and ligase III may complete
the end-joining process (Frit et al., 2014). C-NHEJ is a
more conservative end-joining process, but its efficacy may
be affected by the highly error-prone activity of the
A-NHEJ pathway, the adaptability of the C-NHEJ to repair
irregular ends, and the incompatibility of some DNA ends
(Bétermier et al., 2014).
Homologous recombination (HR)
HR for DSB repair requires a homologous DNA se-
quence provided by the sister homologous chromatid to re-
store a DSB lesion. Therefore, this process is only active
during the S and G2 cell-cycle phases, where this sister
chromatid is available as a template (Krejci et al., 2012).
HR starts with the binding of the MRN complex to the DSB
ends. The MRN complex is constituted by the MRE11 pro-
tein, the rad 50 homolog S. cerevisiae protein (RAD50) and
the nibrin protein (NBS1) (Richard et al., 2011a,b). Then,
the 3 ‘ends of the DSB are digested by the exonuclease ac-
tivity of the MRE11/CtIP to generate free ends at the DSB
that are extended by the EXO1 3’- 5’ exonuclease activity
(Limbo et al., 2007). Subsequently, the single-strand DNA
binding protein 1 (hSSB1) binds to the free 3’ ends and
joins the replication protein A (RPA) to protect these free
ends from further degradation, to prevent inappropriate an-
nealing that could lead to genomic rearrangements and to
prevent hairpin formation (Chen et al., 2013). RPA is a
heterotrimeric complex formed by RPA70, RPA32 and
RPA14 also involved in the control of DNA replication and
repair mechanisms (Sleeth et al., 2007). Then, RPA is re-
placed by an array of RAD51 proteins assembled to eight
BRC domains of the breast cancer 2 (BRCA2) protein and
the participation of five additional proteins
(RAD51B/RAD51C/RAD51D/XRCC2/XRCC3) (West,
2003). Rad51 is a recombinase which forms a pre-synaptic
RAD51-BRCA2 nucleoprotein filament on the DNA (Wil-
liams and Michael 2010). The RAD51-BRCA2 nucleo-
protein filaments search and invade the homologues
sequences to form a Holliday junction structure (Masson et
al., 2001). The sister chromatids are joined by the cohesin
proteins SMC1, 3, 5 and 6. These proteins facilitate the co-
hesion of the DSB and the intact homologous strands to
propitiate the homologous recombination (Kim et al., 2002,
Kong et al., 2014). After the invasion of the sister chro-
matid (synapses) and the alignment of homologous DNA
sequences, RAD51 is removed leaving a free 3’-OH end
enabling the repairing DNA synthesis by the DNA poly-
merase  in the 3’-5’ direction with the help of resolvases,
like the structure-specific endonuclease subunit (MUS81),
the essential meiotic structure-specific endonuclease 1
(EME1), and the Holliday junction 5’ flap endonuclease
(GEN1) (Constantinou et al., 2002). Once the synthesis of
the repaired DNA is completed, these enzymes resolve the
Holliday junction and the DNA ends are joined by the DNA
ligase I (Matos and West 2014). Although not completely
understood, the BRCA1 protein plays an important role in
directing the scaffolding of the Rad51-BRCA2 filaments
and also interacts with the histone H2AX (described below)
during HR repair (O’Donovan and Livingston, 2010).
The HR repair method is considered error-free, be-
cause it uses the homologous sequence of the sister chro-
matid as a template for synthesis. It has been proposed that
chromosome condensation makes it difficult to search for
homologous sequences in the nucleus, and therefore NHEJ
is more frequently employed by cells to repair DSB
(Deckbar et al., 2011; Langerak and Russell, 2011). The
high fidelity of HR is also proposed to explain the low sen-
sitivity and cellular resistance of cells in S/G2 phase to ion-
izing radiation. Therefore it is suggested that resistance to
radiotherapy is mediates by HR (Somaiah et al., 2013).
Single-strand alignment (SSA)
SSA can be regarded as a special form of HR repair.
This repair mechanism is not conservative and is dependent
on the presence of repeated sequences flanking the DSB. It
begins with the cleavage of the 5’-end of one strand of
DNA to expose microhomologies. This is mediated by a
protein complex composed of the CtIP and the MRN com-
plex, followed by the alignment of the homologous ends.
Nonaligned regions are removed by the ERCC1/XPF nu-
cleases (resulting in a loss of nucleotides in the DNA chain)
and then, the DNA ends are joined by the DNA ligase III
(Salles et al., 2011; Liu et al., 2014). Evidence suggests that
SSA repair can elicit the formation of the pathological
chromosome translocations related with cancer (Manthey
and Bailis, 2010).
Radiosensitivity in Breast Cancer Patients
Radiosensitivity is the susceptibility of the cells or
tissues to ionizing radiation. Some patients may be more
sensitive to radiation. Sensitivity results from the toxic ef-
fects of radiotherapy resulting in lesions of the patient’s
normal tissues. These effects may be acute or late, depend-
ing on the time of their manifestation. Acute effects occur
during the treatment or shortly after and they are usually re-
versible and occur in rapidly proliferating tissues, like skin,
gastrointestinal tract and hematopoietic tissues. Late ef-
fects manifest six months or later after the treatment. Late
effects can be permanent, mainly affecting slowly prolifer-
ating tissues such as kidneys, heart, and the nervous system,
and may involve systemic deregulations of the endocrine
system (Barnett et al., 2009). Radiation promotes DSB as
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mentioned above, and this damage is detrimental for ge-
nome integrity (Chistiakov et al., 2008; Rübe et al., 2008;
Henríquez-Hernández et al., 2011).
Mechanisms of hypersensitivity to ionizing radiation
are still unclear, but is estimated that 70% of hypersensitiv-
ity cases are due to genetic variants (Turesson et al., 1996).
As mentioned above, mutations in the ATM gene are associ-
ated with extreme hypersensitivity to ionizing radiation
(Masuda and Kamiya, 2012), and polymorphisms in genes
like XRCC3 and RAD51 increase the risk of radiosensitivity
(Vral et al., 2011). These genes are also implicated in breast
cancer. Mayer et al. (2011) analyzed gene expression in pe-
ripheral blood lymphocytes of breast and cervical cancer
patients. They identified 153 genes altered by ionizing radi-
ation. These genes are involved in cell cycle control and
apoptosis in response to radiation. Of these, 67 genes were
useful to discriminate between normal reacting patients and
subjects with severe radiosensitivity. However, the analy-
ses were performed on lymphocytes, and the authors com-
ment that an analysis of expression in different tissues
would be required to define a more precise gene signature
(Mayer et al., 2011).
The 7,8-dihydro-8-oxo-2’-deoxyguanosine (8-oxo-
dG) base damage is produced by ionizing radiation and is
repaired by nucleotide excision followed by removal of this
abnormal deoxynucleoside out of the cell (Evans et al.,
2010). 8-oxo-dG has been used as a urinary marker of oxi-
dative stress and has been associated with lung cancer
(Il’yasova et al., 2012) and gastrointestinal diseases (Ock et
al., 2012). It has also been proposed as a marker for radio-
sensitivity (Erhola et al., 1997, Roszkowski and Olinski,
2012). Haghdoost et al. (2001) studied 8-oxo-dG urinary
levels in breast cancer patients before and after adjuvant ra-
diotherapy (4 to 6 Gy). Radiosensitive patients showed skin
redness in the radiated areas and significantly increased uri-
nary levels of 8-oxo-dG, and these authors proposed the use
of this deoxynucleoside as a urinary biomarker for radio-
sensitivity. This biomarker facilitates the study of individ-
ual radiosensitivity, since the abnormal metabolite maybe
measured by ELISA (Haghdoost et al., 2001). In a study by
Skiöld et al. (2013), radiation-induced oxidative stress re-
sponse was analyzed by the 8-oxo-dG biomarker in serum
from ex-vivo irradiated leukocytes samples obtained from
breast cancer patients that developed severe acute skin re-
actions (RTOG [Radiotherapy Oncology Group Criteria]
grade 3-4) during radiotherapy and from patients with
breast cancer showing no early skin reactions after radio-
therapy (RTOG grade 0). The authors demonstrated that
patients with RTGO grade 0 showed increased extracellular
serum levels of 8-oxo-dG, in contrast with the significantly
low serum levels observed in patients with RTOG grades 3
and 4, indicating that 8-oxo-dG is a useful biomarker to an-
alyze cellular responses to ionizing radiation (Skiöld et al.,
2013). Nonetheless, 8-oxo-dG can also result from cell ex-
posure to oxidative stress by ROS, as may occur when tis-
sues are exposed to environmental pollutants (Hecht,
1999). For these reasons this biomarker is not specific for
ionizing radiation but, as in the case of the studies by Skiöld
et al. (2013), it is helpful as a comparative ex vivo test of ir-
radiated cells to define the biological effects of ionizing ra-
diation. Extracellular levels of 8-oxo-dG are appropriate
indicators of the cells capability to repair the DNA damage
caused by ROS.
Certain phenotypes of breast cancer have been associ-
ated with locoregional recurrence (LRR). Brollo et al.
(2013) suggested that HER2+ tumors are more susceptible
to ionizing radiation, while Voduc et al. (2010) observed
that LRR seemed higher in patients with triple negative
marker breast cancer, although the number of LRR events
was small. At present, there are no molecular methods to
discriminate between patients with high and low LRR
(Britten et al., 2013). In addition, there is not enough infor-
mation regarding the possible adverse effects of radiother-
apy that may induce genomic and epigenetic modifications
and changes in gene-expression profiles in breast cancer.
Henríquez-Hernández et al. (2011) analyzed isolated
peripheral blood lymphocytes (PBLs) from patients with
advanced breast cancer treated ex vivo with high radiother-
apy doses to study ionizing radiation resistance. They
showed that lymphocytes from patients with low DNA
damage and high apoptosis rates had low risks of radiation
adverse events.
Studies analyzing the type of repair that occurs when
cells are exposed to radiation and the correlation with ab-
normal expression of certain genes involved in DSB repair
have also been conducted. In vitro studies of Bca11 (famil-
ial breast cancer cell line) and Bca10 (sporadic breast can-
cer cell line) cell lines showed high NHEJ repair activity
and direct HR non-conservative repair in the Bca11 cell
line. The Bca10 cell line also showed an increase in non-
conservative repair of direct HR, but to a lesser degree than
Bca11. Consequently, repair mechanisms in these cell lines
may cause deletions in the DNA sequence and cell cycle
deregulation (Keimling et al., 2008). These authors per-
formed a study in PBLs from patients with sporadic breast
cancer, healthy women with familial risk of breast cancer,
and healthy controls, and they demonstrated increased
NHEJ and SSA in both, cancer patients and subjects at he-
reditary risk, vs. the healthy controls. This study suggested
that these two groups are prone to extended non-
conservative DSB repairing mechanisms. Based on these
results, Keimling et al. (2012) implemented a test to ana-
lyze DSB repair in vitro.
Techniques for DSB Repair Analysis
Some tests have been devised to assess DNA damage
in response to diverse substances, microorganisms, or envi-
ronmental conditions. Some of these tests are described be-
low.
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Comet assay
The alkaline comet assay involves measurement of
DNA damage in SSB and DSB. This method is fast and
cheap. It provides important information about the risk of
diseases related to oxidative stress (Alapetite et al., 1999;
Dusinska and Collins, 2008). In this assay, cells are embed-
ded in a thin layer of agarose on a thin glass slide, cells are
lysed in a solution containing detergent and NaCl, releasing
the DNA from the proteins bound to it, but leaving DNA
fragments still attached to the nuclear membrane. Then, the
plate is incubated in an alkaline solution, an electrophoresis
is run and DNA is stained with ethidium bromide. DNA
fragments travel to the anode forming a comet-like image
when viewed by fluorescence microscopy (Fikrová et al.,
2011, Baumgartner et al., 2012). The image of the comet
head denotes the DNA content and the tail the frequency of
DNA breaks (Figure 2B). Software programs designed to
analyze the comet image allow measurement of DNA con-
tent and tail length. The length of the comet tail correlates
with the level of DNA damage.
Hair et al. (2010) used a modified comet assay
method in which slides with cells embedded in agarose
were incubated with three different treatments: 1) alkaline
electrophoresis to detect SSB induced radiation and alka-
line-labile sites; 2) electrophoresis of cells treated with
formamidopyrimidine [Fapy] -DNA glycosylase (Fpg);
this releases the damaged purines, leaving apurinic sites
(AP sites) that are subsequently cleaved with the cellular
AP lyase, producing single strand fragments which can be
visualized in the comet assay, and 3) electrophoresis after
treatment of the cells with bacterial endonuclease EndoIII,
which cleaves the damage strands at sites presenting oxi-
dized pyrimidines, thus increasing the sensitivity of the
comet assay by leaving gaps in mutated bases (Hair et al.,
2010).
Some disadvantages of the comet assay are the vari-
ability between different protocols and between laborato-
ries, which makes it difficult to define ionizing radiation
toxicities, so this issue will require adoption of standard-
ized and comparable protocols (Forchhammer et al., 2010;
Henríquez-Hernández et al., 2012; Azqueta et al., 2014).
Sirota et al. (2014) studied inter-laboratory variation of
comet assay factors, like slide brands, duration of alkali
treatment and electrophoresis conditions, and they found
that laboratory differences were associated with electro-
phoresis conditions, especially the temperature during al-
kaline electrophoresis, which affects the rate of conversion
of alkali labile sites to single stranded breaks (Sirota et al.,
2014). Additionally, it has been suggested that implemen-
tation of a standard software will be required for comet as-
say interpretation (Fikrová et al., 2011).
-H2AX
The histone H2AX variant of the histone H2A is pres-
ent in subsets of nucleosomes (2 to 25% of the total H2A)
and has been implicated in DSB repair. When H2AX is
phosphorylated at the serine residue 139 by phosphoinosi-
tide-3-kinase-related protein kinases (PIKKs), the phos-
phate group adopts a  position in the protein, constituting
the gamma H2AX (-H2AX) configuration (Rogakou et
al., 1998; Rothkamm and Horn, 2009). This phospho-
protein acts in early events of DNA repair by decondensing
the chromatin near the DSB (Kruhlak et al., 2006). Addi-
tionally,  H2AX joins to the DSB ends forming a “H2AX
focus” which is extended for several Mb at the sides of the
DSB. A method used for the analysis of DNA damage is the
measurement of -H2AX using antibodies against
In the -H2AX assays, peripheral blood is collected
and mononuclear cells are separated and fixed on a glass
surface. Then, an immunohistochemistry with anti--
H2AX antibody is performed and the results are analyzed
by fluorescence microscopy in which fluorescent foci are
measured (Figure 2A). This test may be also analyzed by
flow cytometry or by western blot (Kinner et al., 2008;
Dickey et al., 2009; Podhorecka et al., 2010).
-H2AX foci measurements in patients before and af-
ter radiotherapies using low and high doses of ionizing ra-
diation have shown a linear relationship between DNA
damage and exposure to radiation. The initial number of
-H2AX foci is consistent with DSBs in the cells. After a
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Figure 2 - General assays for detecting DNA damage (A) Immuno-
histochemistry with antibodies directed against -H2AX: peripheral blood
mononuclear cells are isolated, nuclei are stained with DAPI and with anti-
bodies directed at -stained H2AX and visualized under fluorescent mi-
croscopy. (B) Comet assay: the comet assay is also performed on mono-
nuclear cells. The cells are embedded in agarose on a thin glass slide, cells
are lysed and incubated in an alkaline solution. Subsequently, DNA frag-
ments are separated by electrophoresis and stained with ethidium bromide.
The comet-like image is viewed under a fluorescence microscope. The
length of the comet tail indicates the frequency of DNA breaks
while, the -H2AX foci disappear due to the DNA repair
(Rübe et al., 2008; Horn et al., 2011). This method is sensi-
tive for measuring DNA repair in patients undergoing ra-
diotherapy, but it is also applied in other fields, such as
DNA damage analysis due to occupational exposure or
contact with environmental pollutants, cigarette smoke,
drugs, etc.. It is important to note that these co-exposures
may affect the results in radiotherapy patients and, hence,
should be considered on an individual basis. Furthermore,
phosphorylation of H2AX is observed in the absence of
DSB in the replication process, in mitosis and during DNA
fragmentation in apoptosis. Therefore, the test must be able
to distinguish between apoptotic and non-apoptotic cells
(Dickey et al., 2009).
Comet assay and -H2AX methods described above
help to assess DNA damage and repair, but do not allow
discrimination of the type of damage, like SSB or DSB. It
is also important to analyze whether the damage is re-
paired and what kind of repair mechanism is operating to
assess whether cells are sensitive or resistant to ionizing
radiation.
Engineered proteins to detect spontaneous DSB
Shee et al. (2013) developed a new synthetic technol-
ogy to quantify DSBs in bacterial and mammalian cells.
This method use the green fluorescent-protein (GFP) fused
to the GAM protein (GAM-GFP), a viral protein from
bacteriophage Mu, which shares sequence homology with
the eukaryotic proteins KU80 and KU70 involved in NHEJ
(Aparicio et al., 2014). Unlike the KU protein, the GAM
protein is not involved in DNA repair reactions. GAM
binds to DNA and inhibits a variety of exonucleases in-
volved in DNA repair (Abraham and Symonds, 1990;
Fagagna et al., 2003; Shee et al., 2013). This advance al-
lows the study and quantification of DNA breaks. In this
method, the I-SceI endonuclease is used to make site spe-
cific DSBs and cells are transfected with a Mu GAM-GFP
fusion expression vector. The GAM-GFP protein joins the
DSBs formed by the I-SceI treatment, generating fluores-
cence at the damaged sites which can be analyzed by fluo-
rescence microscopy. Since the GAM-GFP protein
competes with KU proteins, this results in low levels of
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Figure 3 - Specific assays for detecting DNA damage (A) The EJ-EGFP plasmids contains a mutated version of the EGFP gene (green light bar) created
by inserting a restriction site for the meganuclease I-SceI flanked by a 5 bp microhomology sites (black arrows); this plasmid was designed to be repaired
by NHEJ. The -EGFP/3’EGFP and -EGFP/5’EGFP plasmids contain an array of an EGFP mutated gene containing an I-SceI site (green light bar) fol-
lowed by a spacer (purple bar) and EGFP gene versions truncated at their flanking 3’ and 5’ ends, respectively (dark green bars) which allow the reconsti-
tution of the wild-type version of the marker gene by SSA and HR, respectively. (B) Analysis of DSB repair: The assay is performed in three cultures of
peripheral blood lymphocytes (PBLs), transduced separately with each of the plasmid versions designed for discrimination of SSA, NHEJ and HR. The
cultures are co-transduced with an additional plasmid expressing the I-SceI enzyme. After generating DBS in the target plasmids by the expressed restric-
tion enzyme, DNA repair in PBLs repair by each of the different DNA repair pathway may be monitored by restoration of the wild-type version of EGFP
24 h after transduction by measuring EGFP florescence by flow cytometry.
DNA damage, thus limiting this technology to the study of
DSB repair by HR (Shee et al., 2013).
Identification of repair mechanisms by specific DNA
substrates
As mentioned above, Keimling et al. (2012) devel-
oped an in vitro method in which PBLs are transfected with
marker plasmids for enabling discrimination of the mecha-
nisms involved in DSB repair: HR, NHEJ, and SSA (Figure
3A). In this procedure, PBLs are transduced in three differ-
ent experiments with separate plasmids, each containing
the EGFP reporter gene followedby different sequences
amenable to undergo one of the different mechanisms of
DNA repair defined above. Cells in the three groups are
co-transduced with a plasmid codifying for I-SceI as the in-
ductor of DSB repair events. Fluorescence detection after
24 h by flow cytometry in any of the three transduced cells
of the panel measures the events of each individual operat-
ing mechanism, allowing more detailed information about
DSB repair in individual patients (Figure 3B). This test is
amenable for high-throughput sample processing and anal-
ysis (Boehden et al., 2002; Keimling et al., 2012).
Conclusions
Detection of genetic alterations in genes associated
with breast cancer, particularly genes related to DSB repair,
may allow the diagnosis for genetic patients with breast
cancer, but current methods based on genomic methodolo-
gies to detect mutations are expensive and not suitable for
screening subjects under risk for increased DSB events. Al-
most 20% of the breast cancer patients will show acute
complications due to radiotherapy. Hence, evaluation of
DSB repair is a useful tool for assessing breast cancer risk
and predicting the response and complications associated
with conventional radiotherapy. Methods for studying DSB
repair in PBLs are less expensive and suitable for designing
high-throughput analyses for screening subjects at high risk
for cancer in general, to anticipate adverse events and to of-
fer individualized therapies. These methods will be rele-
vant for preventing unnecessary radiation exposure, for
screening of patients which will not benefit from radiother-
apy, and for adjusting radiotherapy regimes in patients re-
quiring this therapeutic option, in order to avoid adverse
effects associated with DSB in tissues that can ameliorate a
patient’s prognosis.
A general comparison of methods shows that the
comet assay assesses the amount of DNA damage, is inex-
pensive and is easy to perform in conventional laboratories.
However it does not provide detailed information about the
DNA lesion (SSB or DSB) and neither the DSB repair
mechanism (NHEJ, SSA or HR). Another disadvantage of
this method is the inter-protocol and the inter-laboratory
variability in results. Nonetheless, this test is useful as a
preliminary tool for assessing DNA damage. Detection of
-H2AX is also a simple procedure and measurement of
-H2AX may be performed by fluorescent microscopy, but
the technique is also amenable for flow cytometry or west-
ern blot assays, which may render a more precise quantifi-
cation than the comet assay. However, the detection of
-H2AX does not discriminate between SSB and DSB. Fur-
thermore, -H2AX may be phosphorylated during mitosis
or apoptosis, resulting in false positives. The method devel-
oped by Shee et al. (2013) is more sensitive for DSB detec-
tion. It uses the GAM protein linked to EGFP, which joins
the ends of the DSB and prevents DNA repair. Cells with
DSB may be measured by fluorescent microscopy or flow
cytometry. This technique requires molecular and cell biol-
ogy techniques which may constitute an obstacle for diag-
nostic laboratories. The method developed by Keimling et
al. (2012) enables the discrimination and measurement of
the type of DSB repair mechanism. This method also uses
techniques of molecular and cell biology, which may com-
plicate its implementation in diagnostic laboratories, but
this refined technology may have a great impact in defining
a patient’s risk to DSB induced by ionizing radiation.
Further advances in the discovery of genes involved
in DNA repair and additional factors affecting genome sta-
bility will prompt the implementation of better technolo-
gies to study DNA damage in the clinical setting so as to
avoid radiation-related toxicities.
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